73 results about "Rhinitis allergic" patented technology

The invention discloses bifidobacterium animalis and application thereof in allergic rhinitis products, and belongs to the technical field of microorganisms. The technical problem to be solved is that the existing common allergic rhinitis treatment means cannot meet the requirements of patients on safety, long-acting effect and treatment cycle. The invention provides an animal bifidobacterium subsp. Lactis Def +, and after an effective dose of animal bifidobacterium subsp. Lactis Def + is applied to a subject, the animal bifidobacterium subsp. Lactis Def + is found to be capable of remarkably relieving the allergic rhinitis symptom. Specifically, the symptoms of sneezing, dry nose and rhinocnesmus are reduced; the number of nasal septum mucosa intrinsic layer inflammation infiltration cells and nasal septum mucosa epithelium pathological changes are reduced; the IgA and IgE levels of serum are reduced; the levels of proinflammatory factors IL-4, IL-5 and IL-13 are reduced; the normal spleen index is maintained; the imbalance state of Th1 / Th2 and Th17 / Treg is effectively improved, and the body immunity is improved; a safe and long-acting scheme is provided for allergic rhinitis diseases.

The invention discloses an allergic rhinitis diagnosis and allergen traceability system based on dynamic text guidance, and belongs to the technical field of intelligent medical treatment. According to the method, the problems that in the prior art, patient description is inaccurate, allergens are various in variety and have differences, and allergens are difficult to accurately determine and trace are solved, the initial situational sub-graph is verified by introducing periodic features of the patient, the causal contribution degree of the initial situational sub-graph is evaluated through a Bayesian reasoning algorithm, and a mode association result library is formed; according to the method, the crossing of the allergic rhinitis diagnosis and tracing from the traditional static judgment to the dynamic accurate inference is realized, and a personalized and scientific allergen avoidance scheme is provided for patients; through similarity retrieval, environmental information injection verification and calculation of a mode goodness-of-fit score, under the condition that patient symptoms are in multi-factor mixing, a mixed causal graph is created through a graph fusion technology, and the mode goodness-of-fit score is calculated again, so that the accuracy of obtaining an allergen traceability result in practical application is ensured.

The invention relates to the technical field of rhinitis spray preparation, in particular to a method for preparing allergic rhinitis spray from umbilical cord mesenchymal stem cell exosomes, which comprises the following steps: 1, umbilical cord treatment; 2, culturing umbilical cord mesenchymal stem cells; 3, preparing an umbilical cord mesenchymal stem cell exosome; and 4, preparing the rhinitis spray. The rhinitis spray prepared by the method disclosed by the invention is simpler and more convenient to use. The exosome, the platelet growth factor and other substances in the rhinitis spray well solve the core problems of single curative effect, large side effect, low compliance and the like in the traditional rhinitis treatment, and through the induction and repair functions of the stem cell exosome and the bactericidal ability of the antibacterial peptide, the nasal cavity environment is improved, the anaphylactic reaction is reduced, the nasal mucosa is repaired, and the rhinitis treatment effect is improved. The allergic rhinitis is expected to be fundamentally treated.

The application relates to the technical field of Chinese medicine preparation, in particular to a medicine composition for treating allergic rhinitis and a preparation method and application thereof, and the preparation method of the medicine composition for treating allergic rhinitis is as follows: step 1, preparing mixed Chinese herbal medicine A and mixed Chinese herbal medicine B; step 2, subjecting the mixed Chinese herbal medicine A to enzymatic treatment to obtain an enzymatic product; step 3, adding a synergistic agent and inoculating compound microorganisms into the enzymatic product, carrying out aerobic fermentation, adding the mixed Chinese herbal medicine B, and then carrying out anaerobic fermentation to obtain the medicine composition for treating allergic rhinitis. The medicine composition prepared in the application can not only effectively relieve the behavior symptoms such as scratching nose, sneezing and running nose of allergic rhinitis mice, inhibit allergic IgE immune response, but also efficiently relieve the symptoms of allergic rhinitis patients, and has good treatment effect.

This invention belongs to the field of anti-allergy functional food technology, specifically relating to an anti-allergy composition containing inactivated Akkermansia myxophilus. Existing anti-allergy drugs have side effects. The composition of this invention contains inactivated Akkermansia myxophilus, quercetin, vitamin C, and zinc. This invention can improve allergic rhinitis, alleviate eczema symptoms, and improve allergic constitution by regulating immune balance and inhibiting histamine release. The composition of this invention is stable at room temperature and can be formulated into powder or chewable tablets.

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

The invention relates to the technical field of scheme recommendation, in particular to an allergic rhinitis treatment scheme recommendation method based on artificial intelligence. According to the method, individual feature data of a target individual and individual feature data of historical individuals are merged into a unified data set; determining feature similarity according to the individual feature data of any two individuals in the unified data set; dividing a plurality of reference groups based on the feature similarity, and identifying a target reference group to which the target individual belongs; determining a health state deviation degree based on the clinical manifestation data of the target individual on a plurality of time nodes before intervention, and arranging the health state deviation degree according to time to form health state time sequence data; determining a comprehensive similarity according to the health state time sequence data of the target individual and each historical individual in the target reference group; screening out a high-similarity historical individual set according to the comprehensive similarity; and the candidate treatment schemes are generated based on the historical treatment schemes associated with the set, so that the accuracy of treatment scheme recommendation is improved.

The invention belongs to the technical field of medicine, and discloses an artemisia annua pollen allergen sublingual drop as well as a preparation process and application thereof.The preparation is realized through the following core processes: firstly, performing raw material screening and supercritical CO2 degreasing pretreatment on artemisia annua pollen at the full-bloom stage in North China, then performing graded ultralow-temperature freezing and crushing, and performing freeze drying to obtain the artemisia annua pollen allergen sublingual drop. The particle size D90 of the superfine powder is smaller than or equal to 4 microns; then adopting a neutral protease and pectinase composite enzymatic hydrolysis system, and combining 4 DEG C low-temperature pulse ultrasound-assisted treatment to accelerate the dissolution of allergens; carrying out tangential flow grading purification and buffer solution replacement by virtue of 100kDa and 5kDa PES (Polyether Sulfonate) ultrafiltration membranes, and introducing a compound stabilizer; and finally, performing three-stage sterile filtration, and performing encapsulation and preservation. According to the process, through multi-link collaborative optimization, the extraction efficiency and activity stability of allergens are improved, and the prepared sublingual drops have the effects of improving allergic rhinitis, allergic asthma and airway inflammation and also have excellent permeability.

The present invention provides a novel multi-strain probiotic formulation and relates to the use of the multi-strain formulation in therapy, in particular for the treatment or prevention of immunological or allergic diseases / disorders, such as allergic rhinitis or allergic conjunctivitis. In addition, the present invention also provides a novel therapeutic regimen that is easy to follow using the probiotic formulations provided herein.

The application discloses a traditional Chinese medicine composition for benefiting qi and moistening dryness and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine. The composition is composed of 10-15 parts of Huangqi, 10-15 parts of Guizhi, 10-15 parts of Baishao, 10-15 parts of Dazao, 10-12 parts of Zhigancao, 5-8 parts of Mahuang and 6-9 parts of Shanyurou. The preparation method is to decoct with water, add or not add accessories after concentration, and prepare oral dosage forms such as decoction and granules. The application is based on the theory of 'yang qi is soft and can nourish tendons' and 'qi can produce saliva', takes the core principle of warming yang, benefiting qi, transforming qi and producing saliva, restores the qi transformation function of the human body, transpires and transmits water and liquid to the oral cavity, and is specially used for treating xerostomia of the type of yang deficiency and saliva not ascending and the type of qi deficiency and not spreading. Through clinical observation on 180 cases, the total effective rate of the application reaches 90.8%, which is obviously better than that of traditional yin nourishing treatment (48.3%). The composition is warm and not dry, and is used for treating diseases caused by yang deficiency and unstable defensive qi, such as body deficiency cold, allergic rhinitis, spontaneous sweating and the like.

A method for determining the indication for the prevention of persistent AR in the form of problem-based learning in primary school children, consisting of determining the body mass index (BMI, kg / m 2 ) within the range of +1 SDS or more, taking into account the age and sex of the child and IL 1β using the enzyme immunoassay method; with IL 1β equal to or more than 0.029 pg / ml, a child with overweight / obesity is classified as being at high risk for the development of persistent AR, requiring prevention in the form of problem-based learning.

This invention provides a quality testing method for nasal drops used to treat allergic rhinitis, belonging to the field of pharmaceutical testing. Specifically, it includes the following steps: S1. Preparing a test solution; S2. Preparing a mixed reference solution; S3. Separately sampling the reference solution and the test solution for analysis; S4. Generating a reference fingerprint chromatogram. This invention can present all different types of components of the medicinal materials on a single chromatogram through a single test, allowing for simultaneous determination of multiple components and achieving comprehensive and accurate quality control of Artemisia annua and Scutellaria baicalensis nasal drops. The quality assessment method provided by this invention has optimized chromatographic conditions and undergone methodological validation, possessing the advantages of method stability, good repeatability, and stable and reliable test results.

This application discloses a sustained-release formula and medicated pillow for the prevention and treatment of allergic rhinitis, including a pillow base with two symmetrically arranged sustained-release mechanisms and a drive mechanism in the bottom mounting compartment. The sustained-release mechanism consists of multiple sustained-release components, each containing a sustained-release tube and a drug storage tube, connected by a U-shaped connecting pipe and a one-way valve; the drug storage tube is inserted into a pierced tube with a filter screen, which balances air pressure and prevents contamination. The drive mechanism drives a sliding valve to reciprocate via a worm gear system, achieving quantitative drug extraction and precise sustained-release; the atomization design of the sustained-release port improves drug absorption efficiency, and the guide holes in the mounting compartment and the ventilation grooves on the pillow surface form a uniform diffusion channel. This solution solves the problems of cumbersome drug replacement, uncontrollable volatilization, and easy deterioration associated with traditional medicated pillows, offering advantages such as precise controlled release, convenient maintenance, and multiple safety protections. It allows for individualized drug administration based on drug characteristics and patient rhythms, significantly improving the effectiveness of sleep aid therapy and the user experience.

The invention relates to a traditional Chinese medicine technology, and discloses a nasal irrigation traditional Chinese medicine composition for treating allergic rhinitis, a traditional Chinese medicine preparation as well as a preparation method and application thereof. The traditional Chinese medicine composition contains herba epimedii, processed rhizoma atractylodis, pericarpium citri reticulatae viride and halite. The preparation method of the traditional Chinese medicine preparation comprises the following steps: decocting herba epimedii, prepared rhizoma atractylodis, pericarpium citri reticulatae viride and halite with water I at least twice to obtain an extracting solution I, concentrating the extracting solution I, and drying to obtain a dry extract; or the herba epimedii, the processed rhizoma atractylodis and the green tangerine peel are decocted with water II at least twice to obtain an extracting solution II, the extracting solution I is concentrated II to obtain a concentrated solution, and the concentrated solution is mixed with halite. The traditional Chinese medicine composition can effectively absorb medicine components through nasal mucosa through formula compatibility, quickly reaches target organ parts, takes effect quickly and treats both symptoms and root causes.

The present application relates to a kind of pharmaceutical compositions for preventing and treating allergic rhinitis symptoms, with glycerin 1%~10%, polysorbate 80 0.1%~2%, sodium edetate 0.01%~1% and pharmaceutically acceptable carrier in composition by weight percentage.The composition of the present application scientifically screens components and proportion, can form long-lasting antibiofilm protective layer on nasal mucosa, regulate the rhinitis caused by nasal mucus secretion abnormality due to environment or disease and the like, and has the advantages of good biocompatibility, fast effect, good stability, long-acting water-locking, long-acting, no side effects and the like.

The present invention relates to methods of treating hypogonadism in a male subject through administering intranasally to the male subject an intranasal testosterone bio-adhesive gel formulation to deliver a therapeutically effective amount of testosterone. In particular, the testosterone therapy of the invention remains effective if an allergic rhinitis event occurs in the male during the treatment or when the male subject uses a topical nasal vasoconstrictor or a topical intranasal decongestant during the hypogonadism treatment. Further, the present invention relates to a method of preventing Hie occurrence of an allergic rhinitis event in a male, who is undergoing a hypogonadism treatment with an intranasal testosterone bio-adhesive gel. In certain embodiments, the intranasal testosterone bio-adhesive gel formulation according to the invention comprises 4.0% and 4.5% testosterone.

The invention relates to the technical field of biological medicine, in particular to selenium and application of a selenium composition, a nasal composition and application of the nasal composition. The invention provides application of selenium in inhibition of nasal cavity or airway epithelium inflammatory factor expression and a nasal composition containing the selenium. The selenium element is used for regulating and controlling a signal channel, so that the expression of key inflammatory factors in epithelial cells of the nasal cavity or the airway is effectively reduced, the level of reactive oxygen species (ROS) of the epithelial cells of the nasal cavity or the airway is reduced, and the dual effects of inflammation resistance and oxidation resistance are achieved. Therefore, the nasal composition containing the selenium element can effectively block the preinflammatory syndrome driven by upstream oxidative stress by regulating and controlling dual mechanisms of inflammation and oxidative stress reaction, and nasal cavity or airway diseases such as rhinitis and allergic rhinitis are relieved and treated from the source.

The present application relates to treatment of nasal cavity inflammation and mucus hypersecretion. One aspect of the present invention is a method of treatment of rhinitis and rhinosinusitis, wherein the treatment reduces nasal stuffiness, nasal congestion, and phlegm secretion. Reduction of phlegm secretion from the nasal cavity into the pharynx can also reduce cough frequency from infectious and allergic rhinitis. In the preferred embodiment, FEMA 4557, is an example of a molecule, topically applied to the nasal mucosa, that can be used to treat rhinitis. FEMA 4557 is a potent non-irritating suppressor of acute inflammation in the nasal cavity and sinuses, a property not previously described for other topical cooling agents. Thus, FEMA 4557 and related analogs may have therapeutic utility for treating nasal inflammation and mucus hypersecretion.

The present application relates to the technical field of health food, in particular to a plant composite powder and a preparation method and application thereof. The plant composite powder comprises the following components in parts by weight: 1-20 parts of small green oranges, 1-30 parts of Chinese yam, 3-30 parts of perilla leaves, 10-50 parts of lilies, 1-10 parts of fried small red beans, 0.1-1 parts of white kidney beans, 1-30 parts of snow pears, 0.1-5 parts of white horse beans, and 0.05-1 parts of mogroside. The present application combines lilies and small green oranges with the effect of soothing nerves and helping sleep with perilla leaves with the effect of promoting lung and dredging collaterals, and adds Chinese yam and white horse beans for invigorating spleen and replenishing qi, fried small red beans and white kidney beans for removing dampness and swelling, snow pears for nourishing yin and moistening dryness, and mogroside for adjusting flavors, to form a synergistic formula based on the theory of heart-spleen-lung coordination, so as to achieve the dual effects of improving sleep and relieving allergic rhinitis.

The invention belongs to the technical field of biological medicines, and particularly relates to an enzyme-responsive nasal delivery nano-micelle for treating allergic rhinitis as well as a preparation method and application of the enzyme-responsive nasal delivery nano-micelle. The preparation method comprises the following steps: activating a PLGLAG solution, adding a lactoferrin solution, and carrying out a cross-linking reaction to prepare an LF-PLGLAG solution; then, an activated vitamin E succinate solution is added for a cross-linking reaction, and LF-PLGLAG-TOS triblock copolymer micelles are obtained; the preparation method comprises the following steps: stirring and mixing a chitosan solution and LF-PLGLAG-TOS triblock copolymer micelles; the CS / LF-PLGLAG-TOS composite micelle is prepared, and then linarin is added, so that the compound micelle is prepared. The constructed nano-micelle integrates stable drug loading, mucous membrane penetration, active targeting, immunoregulation and intelligent drug release, and provides a safe and efficient novel drug delivery strategy with clinical transformation potential for treatment of allergic rhinitis.

The invention discloses an application of N-(4-methoxyphenyl)-4-(4-methoxyphenyl) benzenesulfonamide in preparation of drugs for treating allergic diseases, and belongs to the technical field of biological medicines. The invention discloses a new pharmaceutical application of N-(4-methoxyphenyl)-4-(4-methoxyphenyl) benzenesulfonamide for the first time, and the N-(4-methoxyphenyl)-4-(4-methoxyphenyl) benzenesulfonamide serving as an anti-allergic antagonist can effectively inhibit phospholipase C activity of stimulated cells and mediated calcium mobilization thereof in vitro. And the effective dose of the desloratadine, which is a positive drug, is lower in vivo to generate a comparable anti-allergic effect with the desloratadine. Meanwhile, in animal models of allergic rhinitis and atopic dermatitis, compared with a positive drug desloratadine, the compound can effectively inhibit the pathological progress of diseases at a lower dosage. Therefore, the compound has a definite effect of inhibiting in-vitro and in-vivo anaphylaxis, and can be effectively applied to the development of drugs for treating allergic diseases.

The invention relates to the field of biological medicine, in particular to application of IL-24 recombinant protein to preparation of medicine for treating allergic rhinitis. By utilizing the IL-24 recombinant protein, the level of local 2-type inflammation of the nasal mucosa can be reduced, expression of inflammatory factors such as IL-4, IL-5 and IL-13 and chemotactic factors such as CCL24 and CCL26 can be reduced, local inflammatory cell infiltration of the nasal mucosa can be relieved, and symptoms such as sneezing and nose catching of patients can be relieved. Meanwhile, a new treatment choice is provided for patients who are invalid in hormone resistance or desensitization treatment.

This invention relates to the field of biomedical technology and proposes a biomarker for reflecting the efficacy of hormone therapy for allergic rhinitis and its application. The biomarker includes one or more combinations of IFNGR1, Furin, and CSF1R. The biomarkers IFNGR1, Furin, and CSF1R of this invention can all differentiate between hormone-sensitive and hormone-insensitive rhinitis. Their expression levels in the nasal secretions of patients with hormone-insensitive allergic rhinitis are significantly lower than those of patients with hormone-sensitive allergic rhinitis, thus reflecting the efficacy of hormone therapy for allergic rhinitis. Furthermore, compared with a single biomarker, the combination of the three biomarkers has better discriminative ability and better efficacy, providing important evidence for subsequent treatment of allergic rhinitis.

The invention belongs to the technical field of medicines, and relates to medical application of nasosinusitis orifice-opening granules. Animal experiments show that the nasosinusitis orifice-opening granules remarkably reduce the sneezing frequency of allergic rhinitis, reduce the nose scratching frequency, effectively reduce the level of IgE and histamine in serum of a mouse suffering from allergic rhinitis, and improve the curative effect of the nasosinusitis orifice-opening granules on allergic rhinitis, so that the nasosinusitis orifice-opening granules can be used for treating allergic rhinitis. The nasosinusitis orifice-opening particle can effectively treat allergic rhinitis and has a wide application prospect.

The invention relates to the technical field of biological medicines, and provides a high VEGF protein / miR-210 extracellular vesicle induced by a serum-free combined culture medium and application of the high VEGF protein / miR-210 extracellular vesicle. According to the invention, high VEGF protein / miR-210 extracellular vesicles are obtained based on induction of a serum-free culture medium; the serum-free culture medium comprises a basic culture medium component combination: sugar-free RPMI1640 and MCDB131 in a volume ratio of 4: 1; the metabolic regulation additive is prepared by synergistically adding sodium pyruvate, cysteine and a proline hydroxylase inhibitor and taking alanine glutamine as an energy substitute; the growth factor is a combination of polyvinyl alcohol, 4-hydroxyethylpiperazine ethanesulfonic acid, ITS-X, epidermal growth factors and basic fibroblast growth factors, wherein the ITS-X, the epidermal growth factors and the basic fibroblast growth factors are added before use. CD63 and CD81 are specifically expressed on the surface of the prepared high VEGF protein / miR-210 extracellular vesicle, the high VEGF protein / miR-210 extracellular vesicle is rich in VEGF protein and miR-210, and the high VEGF protein / miR-210 extracellular vesicle is applied to targeted therapy of allergic rhinitis by inhibiting Th2 type immunoreaction.

This invention provides a method for preparing a thermosensitive gel for the prevention and treatment of nasal diseases and its application. By weight and volume percentage, it comprises recombinant human type III collagen, mussel adhesive protein, an anti-allergy agent, traditional Chinese medicine extracts, thermosensitive materials, and a sodium pyruvate-cocamidopropyl betaine ion-pair complex. This invention, by pre-forming the ion-pair complex, simultaneously solves the technical problems of existing nasal gels, such as poor anti-dilution ability, short adhesion time, and easy inactivation of active ingredients. The product is liquid below 30°C and can be sprayed for complete nasal coverage. At body temperature, it transforms into a gel within 2 minutes for long-lasting adhesion, exhibiting rapid anti-inflammatory, nasal patency-clearing, antipruritic, and mucosal repair effects. It is suitable for the prevention and treatment of allergic rhinitis and sinusitis, as well as nasal wound care, with significantly better efficacy than similar commercially available products.

The application belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating allergic rhinitis and allergic dermatitis, a traditional Chinese medicine preparation and a preparation method. The traditional Chinese medicine composition is prepared from the following raw materials in parts by mass: Shouwuteng 1000-2000 parts, Digupi 1000-2000 parts, Baijianpi 800-1600 parts, Baizhi 600-1800 parts, Kuanfenghua 300-1100 parts, Jinyinhua 300-700 parts, Yekuhua 200-800 parts, Huaihua 400-600 parts and Gancao 400-1000 parts. The nine traditional Chinese medicine raw materials of the traditional Chinese medicine composition are used as monarch, minister, assistant and envoy, and the nine medicines are used together to achieve the effects of cooling blood and detoxifying, nourishing blood and dispelling evil, dispelling wind and relieving itching, and promoting lung and descending qi. Pharmacological experiments show that the formula can significantly reduce inflammatory factors in blood of allergic dermatitis mice, and the effect is good. In addition, the optimal extraction process of the nine medicines is selected, the preparation process is researched, the types and the optimal ratio of the excipients are investigated, and the experimental basis can be provided for hospital preparation registration, so that the traditional Chinese medicine composition can serve allergic disease patients such as AD and AR as early as possible.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating allergic rhinitis, orifice-warming and nose-refreshing oil as well as a preparation method and application of the orifice-warming and nose-refreshing oil. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 4-8 parts of amomum cardamomum, 4-8 parts of alpinia katsumadai, 6-10 parts of pericarpium citri reticulatae, 6-10 parts of fingered citron, 2-6 parts of galangal, 2-6 parts of mint, 4-8 parts of amomum tsao-ko, 4-8 parts of schisandra chinensis, 2-6 parts of immature bitter orange and 2-6 parts of fructus aurantii. By inhibiting excessive activation of immune cells and release of inflammatory mediators such as histamine and interleukin, stimulation of allergic mediators to nasal mucosa is reduced, so that inflammatory response is relieved, nasal mucosa barrier integrity is protected, invasion of external allergens to mucosa is reduced, allergic attack frequency is reduced, and symptoms such as nasal obstruction and clear nasal discharge are relieved. Comprehensive intervention on the allergic rhinitis is realized through ways of inhibiting inflammatory response, protecting mucous membrane barrier, relieving local discomfort and the like, and clinical symptoms of patients are effectively improved.